Skip to contentA
Actinium Pharmaceuticals, Inc.
A
ATNMActinium Pharmaceuticals, Inc. Q3 2025 · 10-Q
Revenue$90.00K$90.00Kno prior Q3 2024 on file Net Income-$5.13M-$5.13MN/M vs Q3 2024 EPS Diluted-$0.16-$0.16N/M vs Q3 2024 Operating Income-$5,692,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-6324.4%
Net margin-5701.1%
ended Sep 30, 2025 · filed Nov 14, 2025 · 45 d after period end